Featured Research

from universities, journals, and other organizations

Rats With Partial Parkinson’s Damage In The Brain Show Complete Functional Recovery After Gene Therapy

Date:
April 1, 2002
Source:
University Of Florida
Summary:
Scientists report this week they have demonstrated that the injection of two corrective genes into a specific brain region generated significant restoration of normal limb movement in rats with a chemical-induced form of Parkinson’s disease.

GAINESVILLE, Fla. --- Scientists report this week they have demonstrated that the injection of two corrective genes into a specific brain region generated significant restoration of normal limb movement in rats with a chemical-induced form of Parkinson’s disease. The findings – by a team of researchers from the University of Florida in Gainesville and Lund University in Lund, Sweden – are published in the current online version of the journal of the Proceedings of the National Academy of Sciences. Neuroscientists Anders Bjorklund of Sweden and Ronald Mandel with UF said the strategy that proved effective in the rodents is not a cure for Parkinson’s disease, but is expected to lead to a better method for delaying and controlling symptoms of the progressively disabling condition. About 1 million Americans are affected by Parkinson’s disease, which occurs most often between the ages of 65 and 90.

Related Articles


"We found that the simultaneous delivery of two selected genes, coupled with a powerful gene-activating agent, works like a pump to prime the production of L-dopa, which is then converted into dopamine by appropriate nerve cells in the brain," said Mandel, a professor of neuroscience with UF’s Evelyn F. and William L. McKnight Brain Institute and the UF Genetics Institute. Dopamine is a neurotransmitter chemical that plays a lead role in coordinating limb movements.

Limb impairments were completely reversed in rats that had near-total Parkinsonian lesions on only one side of the brain, meaning that some of their dopamine-producing cells remained intact. These partial lesions mimic the kind of damage (progressive death of L-dopa-producing cells) found in people with the disease, according to the scientists. Even in the rats with complete destruction of dopamine-producing cells, the delivery of gene therapy resulted in a limited amount of restored motor function. "Quite frankly, I was surprised by this successful outcome, since our previous experiments in the same animal model failed to result in restored motor function," said Mandel.

One key to success, he said, was to figure out how much L-dopa the corrective genes need to generate to produce long-lasting functional effects. "Our team was first to determine this critical threshold," he said. The experiment that helped the rats regain motor function involved a single injection of two different genes, each packaged separately along with the selected gene promoter in a gene-transport molecule (vector). Both genes code for enzymes essential to triggering production of L-dopa. Based on prior discoveries by Dr. Bjorklund, the researchers injected these genes into the striatal region of the forebrain, the destination point of dopamine-producing cells. When the injected vectors land in this area, they deposit their payload of genes, which are "turned on" by the gene-promoter (a selected segment of DNA) to initiate L-dopa production.

Mandel said videotapes of the rats moving about in tall clear-glass cylinders provide the most visible demonstration of the spontaneous behavior regained after gene therapy. Initial tapes show healthy rats standing up and exploring the sides of the cylinder with their front paws while walking around on their hind legs. In the next tapes, taken after the induction of Parkinsonian lesions, the rats can be seen dragging one limp and rigid front paw while walking around and exploring their environment with the normal front limb. Then, in videos taken after gene therapy, the same rats demonstrate normal function of both front paws.

The vector used for the studies was the apparently harmless adeno-associated virus, or AAV, developed at UF as a gene carrier in the early 1980s by Nicholas Muzyczka, an eminent scholar with the UF Genetics Institute and a co-researcher in the Parkinson’s study, and Dr. Kenneth Berns, molecular biologist. UF holds the patent on use of the AAV vector in the brain.

Mandel said the effectiveness of gene therapy in the Parkinsonian rats generates hope that the therapy can eventually be applied in humans, with the potential to double the time a person with Parkinson’s disease will respond well to standard medications. Typically a patient responds well to medication for three to five years, but the beneficial effects gradually diminish because side effects begin to reduce the therapeutic value of the drug.

"Before the U.S. Food and Drug Administration may approve this type of therapy for human testing, we have to solve a critically important problem," said Muzyczka, who also is co-director of the Powell Gene Therapy Center at UF. "The gene promoter we’re now using stays turned on continually, resulting in continuous dopamine production unlike the way our bodies adjust this production to meet our needs. We need a gene regulator that functions more like a rheostat to turn dopamine production on and off as needed to sustain normal limb movement."

UF researchers now are investigating several promising candidate gene promoters. Muzyczka said he is optimistic that human application may occur in about five years.

"We anticipate gene therapy will offer a way to help patients with Parkinson’s disease live many years longer free of disabling symptoms," Mandel said. "There is no reason why gene therapy couldn’t also be given in addition to medication and surgical procedures such as pallidotomy, or deep-brain stimulation."

The research reported in the journal results from more than four years of studies involving nearly 200 rats. Funding came from the Swedish Medical Research Council, and the Knut and Alice Wallenberg Foundation.


Story Source:

The above story is based on materials provided by University Of Florida. Note: Materials may be edited for content and length.


Cite This Page:

University Of Florida. "Rats With Partial Parkinson’s Damage In The Brain Show Complete Functional Recovery After Gene Therapy." ScienceDaily. ScienceDaily, 1 April 2002. <www.sciencedaily.com/releases/2002/04/020401075214.htm>.
University Of Florida. (2002, April 1). Rats With Partial Parkinson’s Damage In The Brain Show Complete Functional Recovery After Gene Therapy. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2002/04/020401075214.htm
University Of Florida. "Rats With Partial Parkinson’s Damage In The Brain Show Complete Functional Recovery After Gene Therapy." ScienceDaily. www.sciencedaily.com/releases/2002/04/020401075214.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins